Hypertension and nephrology

[How the recognition and treatment of primary aldosteronism could be improved?]

BAJNOK László

FEBRUARY 20, 2018

Hypertension and nephrology - 2018;22(01)

[Practically there were no randomized, controlled trials in the area of PA so far, but recently two such ones have appeared. In addition, both are paradigm- forming; yet not built into (yet?) the expert opinions. In the field of primary aldosteronism (PA), there is a sharp contrast between the world’s leading experts in many areas. There is consensus in respect that hypokalaemia, therapy resistance and vascular complications are more common in PA than in primary hypertension. According to prestigious studies, the ratio of surgically correctable cases can be around 5% of hypertension. However, only a tiny fraction of these cases are ever investigated even in the developed countries. Specific treatment might be reached more easily by a multi-speed approach applicable for domestic conditions in which one of the alternatives is the diagnostic process itself. In the latter, following aldosterone criteria are proposed: at screening greater than 15 ng/dl when associated with low renin, in the suppression test, for further testing (adrenal CT) a concentration above 5 ng/dl. This would provide a sufficient balance between sensitivity and specificity. Another solution could be the more widespread use of low dose spironolactone in resistant hypertension.]

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[A Letter to Our Readers]

ALFÖLDI Sándor, KÉKES Ede

Hypertension and nephrology

[Press Release of the Hungarian Society of Hypertension Concerning the New American Hypertension Limit – the Hungarian Limit Remains 140/90 mmHg Still!]

Hypertension and nephrology

[Article Reports]

VÁLYI Péter

Hypertension and nephrology

[Remembering Professor László Kovács MD ]

REUSZ György, KÉKES Ede

Hypertension and nephrology

[The 1st Szekszárd Hypertension Days ]

BENCZÚR Béla

All articles in the issue

Related contents

Hypertension and nephrology

[Fenestration of endothelium of juxtaglomerular arteriole]

ROSIVALL László

[For the first time, we demonstrated the fenestration in the endothelium of the distal portion of renal afferent arteriole (AA), which is unusual among high pressure vessels. The fenestrae are co-localized with renin producing granular epithelioid cells; this arrangement makes it likely that the relatively large renin molecules may use this path to enter into the plasma. We also demonstrated that the length and area of this fenestrated segment 1) correlates with the activity of the renin-angiotensin system (RAS), 2) may change by age, in response to some stimuli such as thirst and in some diseases, 3) allows filtration of fluid prior to the glomerular filtration, which can be as high as about 30% of GFR. This morphology and the high filtration volume in AA is one of the most striking observations of renal microcirculation, and question several basic renal physiological issues.]

Hypertension and nephrology

[Direct renin inhibitors]

FARSANG Csaba

[The mechanisms of action of direct renin inhibitors and the important clinical findings gained by the first, clinically approved drug, aliskiren are discussed. The relative lack of side effects and the very long-lasting antihypertensive action of aliskiren is emphasized. Investigations showing efficacy and protective effects of aliskiren and its combinations with other antihypertensive drugs (diuretics, calcium antagonists, angiotensin converting enzyme inhibitors, angiotensin receptor blockers) against hypertension-induced subclinical organ damage as well as still ongoing clinical trials are also described.]

Hypertension and nephrology

[About the care of patients with hyperuricaemia and gout]

[This consensus document is intended to provide guidance for the effective and efficient treatment of asymptomatic individuals with high uric acid levels and gout patients.]